Bank of New York Mellon’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Bank of New York Mellon’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-191,357	Closed	-$48.8K	–	4534
2023 Q1	$48.8K	Sell	191,357 -3,044	-2%	-$2.75K	﹤0.01%	4201
2022 Q4	$229K	Buy	194,401 +26,550	+16%	+$55.8K	﹤0.01%	3913
2022 Q3	$342K	Buy	167,851 +155,952	+1,311%	+$265K	﹤0.01%	3763
2022 Q2	$18K	Buy	11,899 +481	+4%	+$1.88K	﹤0.01%	4505
2022 Q1	$58K	Buy	+11,418	New	+$51.9K	﹤0.01%	4500

Bank of New York Mellon's PEAR Position: Q2 2023 in Review

Bank of New York Mellon sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 191,357 shares — an estimated $48.8K sold.

Bank of New York Mellon first reported a position in PEAR in Q1 2022 and held it in 5 quarters. The position peaked at $342K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Bank of New York Mellon reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 191,357 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $48.8K.
Bank of New York Mellon first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 5 quarters.
Bank of New York Mellon's Pear Therapeutics, Inc. Class A Common Stock position peaked at $342K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.